乌鸦传媒

Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC

Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease

Better OS, PFS, response rate, but newer combination strategies not included

More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

Confirmed responses in one-fourth to one-third of patients with refractory disease

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

News, features, and commentary about cancer-related issues

Similar outcomes with immediate versus delayed surgery, supporting use of active surveillance

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS

Occurs most often at non-academic and low-volume centers

HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF

Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance

Potential standard of care after current therapies, but key obstacles remain in the way